REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of “Moderate Buy” from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $23.5455.

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley set a $16.00 price target on shares of REGENXBIO in a research report on Friday, May 15th. Barclays dropped their price target on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. HC Wainwright dropped their price target on shares of REGENXBIO from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Bank of America dropped their price target on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th.

REGENXBIO Price Performance

Shares of RGNX stock opened at $6.66 on Monday. The firm has a 50 day moving average price of $7.98 and a two-hundred day moving average price of $10.23. The company has a market capitalization of $344.32 million, a PE ratio of -1.19 and a beta of 1.04. REGENXBIO has a 12-month low of $5.45 and a 12-month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.36). The company had revenue of $6.39 million for the quarter, compared to analyst estimates of $25.84 million. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%. As a group, research analysts expect that REGENXBIO will post -3.69 EPS for the current year.

Insider Buying and Selling at REGENXBIO

In other news, insider Steve Pakola sold 15,309 shares of REGENXBIO stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $11.02, for a total value of $168,705.18. Following the completion of the sale, the insider directly owned 232,617 shares in the company, valued at approximately $2,563,439.34. The trade was a 6.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 14.22% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aquatic Capital Management LLC acquired a new stake in shares of REGENXBIO in the third quarter valued at approximately $37,000. Jones Financial Companies Lllp increased its stake in REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 1,270 shares during the last quarter. Entropy Technologies LP bought a new position in REGENXBIO in the first quarter valued at approximately $87,000. Captrust Financial Advisors bought a new position in REGENXBIO in the second quarter valued at approximately $85,000. Finally, Balyasny Asset Management L.P. bought a new position in REGENXBIO in the fourth quarter valued at approximately $150,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.